# Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252

> **NCT06126744** · PHASE1 · RECRUITING · sponsor: **Duke University** · enrollment: 51 (estimated)

## Conditions studied

- Recurrent High Grade Glioma

## Interventions

- **BIOLOGICAL:** MVR-C5252

## Key facts

- **NCT ID:** NCT06126744
- **Lead sponsor:** Duke University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-11
- **Primary completion:** 2027-12-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06126744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06126744, "Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06126744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*